Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nafulizumab
- Development stage
- Unknown
- Lead developer
- Polpharma Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Nafulizumab is a monoclonal antibody that functions as an anti-PD-1/PD-L1 inhibitor. It is currently under investigation in clinical trials for various cancers, including advanced non-small cell lung cancer and relapsed and refractory cervical cancer. Its mechanism involves blocking the PD-1/PD-L1 signaling pathway, which is crucial for tumor immune escape, thereby enhancing the immune system's anti-tumor effect.
Beyond the preview
Go deeper on nafulizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nafulizumab.